Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.
Chris Mazzolini
Advertisement
Articles by Chris Mazzolini
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
Avoiding Common Ordering Errors in UACR Testing, With Holly Kramer, MD
2
Nationwide Survey Finds Widespread Concern About Topical Steroid Use, Emphasizes Need for Long-Term Management Strategies in Chronic Inflammatory Skin Disease
3
Healthiest States in America: A 2025 Ranking
4
Sebela Submits NDA for Tegoprazan for GERD, Seeking Approval for NERD and Erosive Esophagitis
5